J Korean Med Sci.  2024 Mar;39(8):e90. 10.3346/jkms.2024.39.e90.

Surveillance Systems for Assessing Vaccine Safety: Possibilities and Limitations

• Lee JK

• KMID: 2553331
• DOI: http://doi.org/10.3346/jkms.2024.39.e90

Reference

1. Gonzalez DC, Nassau DE, Khodamoradi K, Ibrahim E, Blachman-Braun R, Ory J, et al. Sperm parameters before and after COVID-19 mRNA vaccination. JAMA. 2021; 326(3):273–274. PMID: 34137808.

2. Baker DW. Trust in health care in the time of COVID-19. JAMA. 2020; 324(23):2373–2375. PMID: 33320208.

3. Kim DH, Kim JH, Oh IS, Choe YJ, Choe SA, Shin JY. Adverse events following COVID-19 vaccination in adolescents: insights from pharmacovigilance study of VigiBase. J Korean Med Sci. 2024; 39(8):e76.

4. Kang D, Choi A, Park S, Choe SA, Shin JY. Safety of COVID-19 vaccination during pregnancy and lactation: a VigiBase analysis. J Korean Med Sci. 2024; 39(1):e3. PMID: 38193325.

5. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011; 72(6):905–908. PMID: 21658092.

6. Weber J. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Rainsford KD, Velo GD, editors. Side-Effects of Anti-Inflammatory Drugs, Advances in Inflammation Research. New York: Raven Press;1984. p. 1–7.